Trade Sale Or IPO for Australia’s Healthscope?
This article was originally published in PharmAsia News
Executive Summary
Investors looking to benefit from growth in the health care provision sector are circling as major Australian hospital operator Healthscope considers a relisting or potential trade sale.
You may also be interested in...
Regulatory And Staffing Challenges For Private Hospitals In Southeast Asia - Private Healthcare World Asia 2011
SINGAPORE - Investor interest in Asia's private hospital infrastructure remains strong but regulatory limitation and lack of professional staff stymies its huge potential, industry experts told a Singapore conference June 15
Prima Shifts Focus To LAG-3 After Immutep Deal
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.
Phylogica Surges On Early CPP Cancer Results
Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.